DCM
VRDN icon

Driehaus Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Driehaus Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-167,934
Closed -$5.23M – 443
2025
Q4 		$5.23M Sell
167,934
-176,150
-51% -$4.83M 0.04% 307
2025
Q3 		$7.43M Sell
344,084
-32,762
-9% -$591K 0.05% 303
2025
Q2 		$5.27M Sell
376,846
-893,635
-70% -$12.1M 0.04% 300
2025
Q1 		$17.1M Sell
1,270,481
-605,395
-32% -$10.3M 0.17% 179
2024
Q4 		$36M Sell
1,875,876
-115,614
-6% -$2.51M 0.3% 111
2024
Q3 		$45.3M Buy
+1,991,490
New +$32.6M 0.39% 88
2023
Q3 		– Sell
-84,019
Closed -$2M – 451
2023
Q2 		$2M Sell
84,019
-322,758
-79% -$8.28M 0.03% 300
2023
Q1 		$10.3M Sell
406,777
-37,555
-8% -$1.2M 0.15% 214
2022
Q4 		$13M Buy
444,332
+107,542
+32% +$2.48M 0.19% 166
2022
Q3 		$6.91M Buy
336,790
+270,717
+410% +$4.87M 0.1% 240
2022
Q2 		$764K Buy
66,073
+16,073
+32% +$216K 0.01% 304
2022
Q1 		$925K Hold
50,000
– – 0.01% 327
2021
Q4 		$989K Hold
50,000
– – 0.01% 310
2021
Q3 		$823K Buy
+50,000
New +$733K 0.01% 326
2021
Q2 		– Sell
-33,333
Closed -$557K – 527
2021
Q1 		$557K Hold
33,333
– – 0.01% 378
2020
Q4 		$548K Buy
+33,333
New +$502K 0.01% 357

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Driehaus Capital Management's VRDN Position: Q1 2026 in Review

Driehaus Capital Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 167,934 shares — an estimated $5.23M sold.

Driehaus Capital Management first reported a position in VRDN in Q4 2020 and held it in 16 quarters. The position peaked at $45.3M in Q3 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Driehaus Capital Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Driehaus Capital Management sold 167,934 Viridian Therapeutics shares in Q1 2026, an estimated $5.23M.
  • Driehaus Capital Management first reported a position in Viridian Therapeutics in Q4 2020 and held it in 16 quarters.
  • Driehaus Capital Management's Viridian Therapeutics position peaked at $45.3M in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.